Email Alert RSS
Volume 14 Issue 5
Sep.  2023
Turn off MathJax
Article Contents
Abstract
References
Related Articles
ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227
Citation: ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227
shu

Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy

  • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

National High Level Hospital Clinical Research Funding 2022-PUMCH-A-021

Beijing Municipal Commission of Sciences and Technology Z211100002921016

Dongcheng District Outstanding Talent Nurturing Program 2022-dchrcpyzz-69

More Information
  • Corresponding author:

    LI Jian, E-mail: lijian@pumch.cn

  • Received Date: May 07, 2023
  • Accepted Date: June 25, 2023
  • Available Online: July 12, 2023
  • Issue Publish Date: September 29, 2023
    Graphical Abstract
    • Abstract
  • Castleman disease (CD) is a group of rare and heterogenous hematological diseases included in the 'Rare disease catalogue' of China. Among the different clinical subtypes of CD, idiopathic multicentric Castleman disease (iMCD) is characterized by symptomatic inflammatory symptoms with poor prognosis. Interleukin-6 (IL-6) targeted therapy (eg. siltuximab) is now considered as the most important treatment option according to international and domestic treatment guidelines and consensus. On July 2022, siltuximab became available in Chinese market, heralding the era of IL-6 targeted therapy in China. Thus, it is a good time point to review the state-of-the-art technology in the field of diagnosis and treatment of CD. We also highlight some of the clinical investigations conducted by Chinese researchers.
    • FullText(HTML)
    • References (13)
  • [1]
    Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma[J]. Cancer, 1956, 9: 822-830. DOI: 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4
    [2]
    Zhang L, Dong YJ, Peng HL, et al. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria[J]. Lancet Reg Health West Pac, 2023, 34: 100720. DOI: 10.1016/j.lanwpc.2023.100720
    [3]
    van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease[J]. Blood, 2018, 132: 2115-2124.
    [4]
    Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease[J]. Blood, 2017, 129: 1646-1657. DOI: 10.1182/blood-2016-10-746933
    [5]
    中华医学会血液学分会淋巴细胞疾病学组, 中国抗癌协会血液肿瘤专业委员会, 中国Castleman病协作组. 中国Castleman病诊断与治疗专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42: 529-534. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWWK202107001.htm
    [6]
    Zhang MY, Jia MN, Chen J, et al. UCD with MCD-like inflammatory state: surgical excision is highly effective[J]. Blood Adv, 2021, 5: 122-128. DOI: 10.1182/bloodadvances.2020003607
    [7]
    Dong Y, Zhang L, Nong L, et al. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease[J]. Ann Hematol, 2018, 97: 1641-1647. DOI: 10.1007/s00277-018-3347-0
    [8]
    Zhang L, Zhao AL, Duan MH, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease[J]. Blood, 2019, 133: 1720-1728. DOI: 10.1182/blood-2018-11-884577
    [9]
    Li Z, Lan X, Li C, et al. Recurrent PDGFRB mutations in unicentric Castleman disease[J]. Leukemia, 2019, 33: 1035-1038. DOI: 10.1038/s41375-018-0323-6
    [10]
    Yu L, Shi M, Cai Q, et al. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study[J]. Oncologist, 2020, 25: 963-973. DOI: 10.1634/theoncologist.2019-0986
    [11]
    Zhou J, Zhang L, Liu X, et al. Evolution of Pulmonary Involvement in Idiopathic Multicentric Castleman Disease-Not Otherwise Specified: From Nodules to Cysts or Consolidation[J]. Chest, 2023. doi: 10.1016/j.chest.2023.03.022.
    [12]
    Zhao H, Zhang M, Shen K, et al. A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in newly-diagnosed iMCD patients[J]. Blood, 2023, 141: 2654-2657.
    [13]
    Zhong NN, Liu B, Bu LL. Exploring Castleman disease in China: pre-IL-6 treatment era and advancements in knowledge[J]. Lancet Reg Health West Pac, 2023, 34: 100747. DOI: 10.1016/j.lanwpc.2023.100747
    • Related Articles

  • Related Articles

    [1]ZHAO Zeqing, PAN Hui, ZHANG Li, WANG Fengdan, CHEN Shi, YANG Xiao, LI Jianchu. Research Status and Application Prospect of Bone Age Assessment by Ultrasonography[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 400-405. DOI: 10.12290/xhyxzz.2023-0270
    [2]LIU Chang, ZHENG Yuchao, XIE Wenqian, LI Chen, LI Xiaohan. Image Recognition Method of Cervical Adenocarcinoma in Situ Based on Deep Learning[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 159-167. DOI: 10.12290/xhyxzz.2022-0109
    [3]ZHAO Chen-yang, ZHU Qing-li, ZHANG Rui, QI Zhen-hong, YANG Meng, JIANG Yu-xin. The Potential Value of Photoacoustic Imaging in the Assessment of Inflammatory Changes of Joints[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 232-237. DOI: 10.12290/xhyxzz.20190139
    [4]Zhi-qun XING, Xiao-ting WANG, Da-wei LIU. Critical Ultrasonography: Hemodynamic Helper[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 461-464. DOI: 10.3969/j.issn.1674-9081.2019.05.007
    [5]Rui-feng LIU, Yu XIA, Yu-xin JIANG. Application of Artificial Intelligence in Ultrasound Medicine[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(5): 453-457. DOI: 10.3969/j.issn.1674-9081.2018.05.015
    [6]Jia-yu MAO, Xiao-ting WANG, Da-wei LIU. Importance of Critical Ultrasonography to Comprehensive Etiologic Management in Critical Care Medicine[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(5): 404-406. DOI: 10.3969/j.issn.1674-9081.2018.05.005
    [7]Hang-ning ZHOU, Feng-ying XIE, Zhi-guo JIANG, Jie LIU, Hong-zhong JIN, Ru-song MENG, Yong CUI. Classification of Skin Images Based on Deep Learning[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(1): 15-18. DOI: 10.3969/j.issn.1674-9081.2018.01.004
    [8]Li-ming XIA, Jian SHEN, Rong-guo ZHANG, Shao-kang WANG, Kuan CHEN. Application of Deep Learning in Medical Imaging Research[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(1): 10-14. DOI: 10.3969/j.issn.1674-9081.2018.01.003
    [9]Fang YAO, Ai-ming YANG, Dong-sheng WU, Xi WU, Tao GUO, Wei-xun ZHOU, Xing-hua LU. Diagnostic Value of Miniprobe Endoscopic Ultrasonography in Assessment of Tumor Invasion Depth in Early Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(2): 83-88. DOI: 10.3969/j.issn.1674-9081.2015.02.002
    [10]Introduction to Vascular Ultrasonography (6th ed.)(2012)[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(1): 87-87.

  • Cited by

    Periodical cited type(5)

    1. 姚晓倩，洪敏萍，蔡宏杰，吴慧青. 基于超声影像组学术前预测浸润性乳腺癌患者腋窝淋巴结状态. 现代实用医学. 2023(01): 116-119 .
    2. 林文华，杨少玲，赫兰，陶均佳，张红珍，顾家红，赵坤，胡静. 基于术前超声及钼靶特征的列线图预测乳腺癌腋窝淋巴结转移的价值. 中国临床医学影像杂志. 2023(09): 647-653 .
    3. 牛梓涵，朱庆莉，姜玉新. 超声在早期乳腺癌腋窝淋巴结转移诊断中的应用进展. 中华超声影像学杂志. 2023(10): 889-893 .
    4. 李玥，曹军英. 多模态超声在乳腺癌精准诊断中研究进展. 临床军医杂志. 2022(07): 661-665 .
    5. 赵萍，闫朝岐，杨学伟，李洋，叶倩. 乳腺癌腋窝淋巴结超声检查评价及研究进展. 中国临床研究. 2022(09): 1270-1272+1291 .

    Other cited types(5)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (328) PDF downloads (85) Cited by(10)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close